PRESSEPORTAL Presseportal Logo
All Stories
Subscribe to Epigenomics AG

19.12.2012 – 11:02

Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics Provides Additional Data on the Outcome of its Head-to-Head Comparison Study of Epi proColon® to FIT

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Research & Development/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX), the German-American cancer molecular
diagnostics company, today provided detailed results from a head-to-head
comparative study between its blood-based colorectal cancer (CRC) detection test
Epi proColon® and fecal immunochemical testing (FIT) for which it recently
reported top-line results. This trial was designed to evaluate non-inferiority
of the blood based Epi proColon® assay performance in comparison to FIT.

The subjects included in the first arm of the study were average risk,
asymptomatic screening patients with no history (own or familial) of CRC. These
patients were identified as CRC patients in the context of screening
colonoscopies performed from April-November 2012 across 70 sites in the US. 

As previously reported, in this study, Epi proColon® was able to detect 73 out
of 103 cancer cases, demonstrating an overall sensitivity of 71%. Clinical
staging information of the disease was available for 71 of the 103 cases. 

Further analysis of the data shows that Epi proColon® was able to demonstrate
61% sensitivity for 23 cases in stages 0 and 1 (FIT 61% sensitivity), 75% for 16
cases in stage 2 (FIT 75% sensitivity), 70% for 20 cases in stage 3 (FIT 85%
sensitivity) and 92% in 12 stage 4 cases (FIT 64% sensitivity). In the 32 cases
of unknown clinical staging, the sensitivity was 69% (57% sensitivity for FIT). 
The correspondence of the blood and stool based test methods was 62%, whereby
Epi proColon® was able to identify 20 cases that could not be identified by FIT,
while FIT identified 17 CRC cases, which were not found through Epi proColon®. 

The second arm of the study comprised 198 average risk individuals, which were
prospectively enrolled (i.e. before colonoscopy). Among these, 3 CRC cases were
identified by colonoscopy. Both, Epi proColon® and FIT were able to find 2 out
of these three CRC cases. At the same time, of the 24 advanced adenomas included
in the second arm, neither method detected a significant number of these. The
adenoma detection for Epi proColon®, as shown in previous studies, was low.
Surprisingly, the finding was the same for FIT, although it was previously
believed to be a distinct advantage of this method. 

Overall reported specificities for Epi proColon® and FIT were at 81% and 98%
respectively. While the point estimate of 81% specificity for Epi proColon® was
still above the pre-defined non-inferiority margin, this result was
statistically non-significant. The difference in specificity is less vital in
the Company's opinion, as patients will undergo a colonoscopy - the currently
recommended screening procedure - as a result of a positive test result. In
addition to this it is noteworthy that the Company's CE marked version of the
product, optimized for specificity and launched in Europe earlier this year, has
a specificity for CRC detection of 99%. This could open additional possibilities
to address the US market in the future.  

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR 
Epigenomics AG 
Tel +49 (0) 30 24345 368

About Epigenomics

Epigenomics ( is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.

Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 

company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English

Original content of: Epigenomics AG, transmitted by news aktuell

More stories: Epigenomics AG
More stories: Epigenomics AG